Provider review
Medro review
Stacks a discount on top of figures that are already floors.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
We may earn a commission at no extra cost to you. Affiliate partners are listed first on our rankings. How we’re funded.
From $149/mo semaglutide and $224/mo tirzepatide
Visit MedroSo the number a first-time reader will actually pay appears nowhere on the page.
Price as published
Medro
From $149/mo semaglutide and $224/mo tirzepatide
- Vs median
- $26/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Two ordinary floors with a discount stacked on top, which produces the odd result that the number you will actually pay for your first plan is not written anywhere. The floors are the cheapest configuration, the discount is a hundred dollars off the first plan, and the standing rate at a working dose is absent — so all three of the figures that would matter are either partial or missing. What the page does well is the parts that are not price. Availability is stated as all fifty states, plainly, where several sellers leave the map vague or bury it. Shipping is included on every order without conditions. And the framing around prescribing is careful — medication only if clinically appropriate after review by a licensed clinician — which is the correct formulation and one plenty of pages in this category skip in favor of implying that approval is a formality. No milligram appears against either figure.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want availability stated plainly for all fifty states
- You want prescribing framed as conditional rather than automatic
- You want free expedited shipping without conditions
Look elsewhere if
- You want to know what your first plan actually costs after the discount
- You want a rate rather than a floor
- You want a dose behind the number
What it actually costs
Price as published
From $149/mo semaglutide and $224/mo tirzepatide
- Vs median
- $26/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate
- Market
- $59–$1,300/mo is the full published spread on this site
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
235 of the 548 programs here price a small dose this way. Two floors with a first-plan discount stacked on top, which produces the odd result that the figure a new patient will actually pay is written nowhere — not the discounted first plan, not the working-dose rate. The non-price disclosure is better: availability stated as all fifty states, and prescribing framed as conditional on clinical review rather than implied to be automatic.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not confirmed
- Labs
- Not required
- Pricing
- Check plan terms
What it does well
- States availability across all fifty states plainly.
- Frames prescribing as conditional on clinical review rather than implying automatic approval.
- Free expedited shipping on all orders, stated without conditions.
Pharmacy, labs and oversight
Medro does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What Medro publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Two ordinary floors and a discount stacked on top, which produces the odd result that the number a new reader will actually pay for their first plan is not written anywhere. The floors are the cheapest configuration, the discount is a hundred dollars off the first one, and the standing rate at a working dose is absent, so all three of the figures that matter are either partial or missing. What the page does well is the parts that are not price. Availability is stated as all fifty states, plainly, which several sellers here leave vague. Shipping is included. And the framing around prescribing is careful — medication only if clinically appropriate after a clinician's review — which is the correct formulation and one that plenty of pages in this category skip in favor of implying approval is automatic. No milligram appears against either figure.
The honest cons
The discounted first-plan price is not written anywhere on the page.
- Both published figures are floors with nothing above them stated.
- No milligram appears against either figure.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
Medro is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.
Also consider
Two more programs that price a small dose the way Medro does. Both are partners: we may earn a commission if you start care through these links.
Partner
Strut Health
$99/mo sema lozenge (auto-refill)
Standard plan, self-directed low dose
FDA warning letter · Strut Health · February 2026 · addressed to Strut Health, LLC dba Strut. Details in our review.
Partner
Peter MD
$149/mo GLP1+B12 · $249/mo tirz (quarterly)
Standard plan, self-directed low dose
Where this sits
#353 of 548
Ordered with the companies that pay us first, and Medro is not one of them. A disclosed partition, not a score.
Compare all 548 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Low dose vs full dose
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
Bodybuilding Health+
$179/mo sema · $209/mo tirz
- Vs median
- $4/mo above the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the Bodybuilding Health+ review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.